SOMNF (SomnoMed) Total Equity: $33.25 Mil (As of Dec. 2025)


SOMNF SomnoMed Ltd SOMNF
49 GF Score
Price $0.45
GF Value $0.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Total Equity?

SomnoMed SOMNF 49 Total Equity is $33.25 Mil as of Dec. 2025. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review.

SomnoMed's total equity for the quarter that ended in Dec. 2025 was $33.25 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SomnoMed Total Equity Historical Data

* Premium members only.

The historical data trend for SomnoMed's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed Total Equity Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.59 19.53 16.45 30.49 30.20

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.01 30.49 30.06 30.20 33.25
SOMNF
49GF Score
SomnoMed Ltd SOMNF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SomnoMed's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=52.715-22.513
=30.20

SomnoMed's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=53.089-19.843
=33.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $33.25 Mil mean?
SomnoMed (SOMNF) has a Total Equity of $33.25 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for SomnoMed and its competitors.
Is SomnoMed's Total Equity too high?
SomnoMed's current Total Equity is $33.25 Mil. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Total Equity compare to ABT and SYK?
SomnoMed's Total Equity of $33.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for SomnoMed and its competitors. SomnoMed's current Total Equity is $33.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $0.45 — trading 35.7% above its estimated fair value. The current Total Equity is $33.25 Mil. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For SomnoMed (SOMNF), the current Total Equity is $33.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33. GuruFocus considers SomnoMed to be Significantly Overvalued.

Key valuation signals for SOMNF:

  • Total Equity: $33.25 Mil
  • GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for SOMNF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.33
GF Value